U.S. Supreme Court Patent Cases Harold C. Wegner * Harold C. Wegner * Costa Rican Bar Association Auditorio Pablo Casafont San Jose, Costa Rica June 8,

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

Welcome to the FICPI ABC Conference © Birch, Stewart, Kolasch & Birch, LLP KSR v. Teleflex: U.S. Supreme Court Decision Raises Patentability Standard.
October 2007KSR Training1 TC 3700 KSR Sample Rejection.
Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Patents in Higher Education: Issues Arising from the Blackboard Case by Bruce Wieder May 29, 2008.
© 2011 Sterne, Kessler, Goldstein, & Fox P.L.L.C. All Rights Reserved. Patenting Biomarkers and Diagnostic Methods Neil P. Shull, Ph.D., J.D. S TERNE,
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
1 1 1 AIPLA American Intellectual Property Law Association Standard for Indefiniteness– Nautilus, Inc. v. Biosig Instruments, Inc. Stephen S. Wentsler.
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
Patent, Trademark, Copyright, and Enforcement - Law and Policy November 5-8, 2007 United States Patent and Trademark Office Global Intellectual Property.
Bilski: Will It Affect Bioscience Method Claims? Mark T. Skoog, Ph.D. Merchant & Gould MIPLA Biotech/Chemical Law Committee November 2009.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
John B. Pegram Fish & Richardson P.C. New York “Divided” or “Joint” Infringement.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
Patents Copyright © Jeffrey Pittman. Pittman - Cyberlaw & E- Commerce 2 Legal Framework of Patents The U.S. Constitution, Article 1, Section 8:
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Vs. Miguel Chan UC Berkeley IEOR 190G March 2009.
Graham v John Deere Patent Law. Justice Tom Clark ( )
KSR vs. Teleflex IEOR 190G Simon Xu
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Indirect and Foreign Infringement Prof Merges Patent Law –
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Intellectual Property Boston College Law School February 16, 2009 Patent – Novelty.
Theresa Stadheim-Schwegman Lundberg & Woessner, PA Sharon Israel – Mayer Brown LLP June 2015 Lexmark v. Impression Products - patent exhaustion issues.
Software Protection & Scope of the Right holder Options for Developing Countries Presentation by: Dr. Ahmed El Saghir Judge at the Council of State Courts.
Nonobviousness II Intro to IP – Prof Merges
Policy Issues Concerning Parallel Trade of Pharmaceutical Drugs in the United States James Love CPTech FDA Prescription Drug Importation Meeting 14 April.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
1 Current Issues in Intellectual Property 112 S. West Street Alexandria, Virginia
Determining Obviousness Under 35 U.S.C. § 103 After KSR v. Teleflex
Patenting Wireless Technology: Obviousness Dr. Tal Lavian UC Berkeley Engineering, CET.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
The Effect of the Supreme Court Decision on Patent Reform Legislation John F. Duffy Professor of Law George Washington University Law School © 2007 John.
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
Chapter 08.  Describes property that is developed through an intellectual and creative process  Inventions, writings, trademarks that are a business’s.
© 2008 International Intellectual Property June 22, 2009 Class 6 Patents: Multilateral Agreements (Paris Convention); Economics of International Patent.
Chapter 5: Patent Protection for Computer Software & Business Methods.
Patent Lawyers Club of Washington, D.C. Current Patent Topics from Inside the Beltway Harold C. Wegner Foley & Lardner LLP March 5, 2008.
Shades of Gray Exhaustion and IP Enforcement in a Global Marketplace.
Oct. 29, 2009Patenting Software and Business Methods - RJMorris 1 2 nd Annual Information Technology Law Seminar Patenting Software and Business Methods.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
Patents IV Nonobviousness
LAW OF COMPUTER TECHNOLOGY FALL 2015 © 2015 MICHAEL I. SHAMOS Patents Michael I. Shamos, Ph.D., J.D. Institute for Software Research School of Computer.
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
#ACIPIV ACI’s 9 th Annual Paragraph IV Disputes Neal K. Dahiya Senior Counsel – Patent Litigation Bristol-Myers Squibb (Princeton, NJ) Limelight v. Akamai:
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex Biotech/Chem/Pharma Customer Partnership Meeting December.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
© 2008 International Intellectual Property June 16, 2009 Class 2 Introduction to Patents.
Exhaustion after Quanta Patent Law – Prof. Merges
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Olek Pawlowski IEOR 190 Spring 2009 UC Berkeley Explaining the basic concepts of the landmark Supreme Court patent case of KSR vs. Teleflex and specifically.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association THE STATUS OF INDUCEMENT Japan Intellectual Property Association Tokyo Joseph A. Calvaruso.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
BLW 360 – January 27, 2015 Jonathan LA Phillips
© 2015 Waller Lansden Dortch & Davis, LLP. All Rights Reserved. Ready to Patent? Value and Risk Considerations Nicolo Davidson.
Where value is law. © 2012 Hodgson Russ LLP PATENT PIRACY: WHEN IS OFFSHORE ACTIVITY INFRINGEMENT? Jody Galvin Melissa Subjeck July.
Introduction to Intellectual Property Class of Sept
Korean Intellectual Property Office October 19, 2011 Sunhee Lee, SUGHRUE MION PLLC RECENT CASES IN BIOTECH/PHARM/CHEM & 2011 AMERICA INVENTS ACT.
The Challenge of Biotech Patent Eligibility in the United States:
Patents IV Nonobviousness
Cooper & Dunham LLP Established 1887
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
US Antitrust Limitations on Patent Licensing
Presentation transcript:

U.S. Supreme Court Patent Cases Harold C. Wegner * Harold C. Wegner * Costa Rican Bar Association Auditorio Pablo Casafont San Jose, Costa Rica June 8, 2010 * Biographical information at the end of this presentation.

Supreme Court Decisions eligible nonobviousness patentability The two major Supreme Court battleground areas for obtaining valid patents deal with patent-eligible subject matter (35 USC § 101) and nonobviousness as a condition for patentability(35 USC § 103)(a)).

Supreme Court Decisions eligibleable Most tangible objects as well as processes are patent- eligible(§ 101), whether or not they are patentableas being nonobvious (§ 103). also patentable E.g., a laboratory-crafted microorganism may be “eligible” (§ 101), and it is also patentable if new and nonobvious (§ 103). But, a second microrgansim may be unpatentableif it is “obvious” versus previously known microorganisms.

Supreme Court Decisions Leading Cases on Patent-Eligibility (35 USC § 101) Bilski v. Kappos: Supreme Court decision expected June 7 or 14 or 21 or 28. Diamond v. Chakrabarty, 447 U.S. 303 (1980)(Rehnquist, C.J.)(patent-eligibility under 35 USC § 101 for “living” inventions).

Supreme Court Decisions Leading Cases on Patentability (35 USC § 103)(a) Is the invention which is patent-eligible under 35 USC 101 also patentable under the nonobviousness test of the leading cases: Graham v. John Deere Co. 383 U.S. 1 (1966) KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 426 (2007).

Supreme Court Decisions The “Obviousness” Inquiry of Graham and KSR “The underlying factual inquiries [for an obviousness determination] are: (1) the scope and content of the prior art, (2) the differences between the prior art and the claims at issue, (3) the level of ordinary skill in the pertinent art, and (4) secondary considerations of nonobviousness.” Perfect Web Techs., Inc. v. InfoUSA, Inc., 587 F.3d 1324, 1327 (Fed. Cir. 2009)(Linn, J.) (citing KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 406 (2007), citing Graham v. John Deere Co., 383 U.S. 1, (1966)).

Supreme Court Decisions common sense “[T]he Supreme Court observed that common sense can be a source of reasons to combine or modify prior art references to achieve the patented invention.” Perfect Web, 587 F.3d at

Supreme Court Decisions common sense When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under § 103.” Perfect Web, 587 F.3d at 1328 (quoting KSR, 550 U.S. at 421(emphasis added).

Supreme Court Decisions “Common sense teaches... that familiar items may have obvious uses beyond their primary purposes, and in many cases a person of ordinary skill will be able to fit the teachings of multiple patents together like pieces of a puzzle.” Perfect Web, 587 F.3d at 1328 (quoting KSR, 550 U.S. at

Supreme Court Decisions Mayo v. Prometheus: Diagnostic Method Patent-Eligibility InMayo Collaborative Services v. Prometheus Laboratories, Inc., Supreme Court No , opinion below, Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 581 F.3d 1336 (Fed. Cir. 2009)(Lourie, J.), the Supreme Court is given the opportunity to grant certiorari concerning the patent-eligibility under 35 USC § 101 of a medical diagnostic method.

Supreme Court Decisions Claim: A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising: administering a drug determining the level “(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and “(b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder “wherein the level of 6-thioguanine less than about 230 pmol per 8x108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and “wherein the level of 6-thioguanine greater than about 400 pmol per 8x108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.”

Supreme Court Decisions Question Presented in Mayo v. Prometheus at the Supreme Court: “Whether 35 U.S.C. § 101 is satisfied by a patent claim that covers observed correlations between patient test results and patient health, so that the claim effectively preempts all uses of these naturally occurring correlations.”

Supreme Court Decisions International Patent Exhaustion the patentee A patent right is “exhausted” when the patentee sells his patented product to a purchaser. Then, the purchaser is free to resell (or otherwise transfer) the thus- purchased product. 13

Supreme Court: Exhaustion same country Does the patentee’s sale have to be in the same country to create “exhaustion”?, is the United States patent right “exhausted” when the patentee sells in the other country Thus, if a patentee has parallel patents in the United States and another country, is the United States patent right “exhausted” when the patentee sells in the other country? If “yes”, this would be “international patent exhaustion”. 14

Supreme Court: Exhaustion the Executive Branch “International patent exhaustion” was strongly opposed by the Executive Branch of the United States in negotiations leading up to the TRIPS, while developing countries were equally adamant that there is (or should be) international patent exhaustion. 15

Supreme Court: Exhaustion The TRIPS treaty failed to reach any agreement on whether there is or should be international exhaustion. Instead, the TRIPS expressly states: nothing in this Agreement shall be used to address the issue of the exhaustion of intellectual property rights “[S]ubject to the provisions of [TRIPS] Articles 3 [providing for national treatment] and 4 [providing most-favored-nation treatment,] nothing in this Agreement shall be used to address the issue of the exhaustion of intellectual property rights.” TRIPS, Article 6. 16

Supreme Court: Exhaustion The Supreme Court in has never yet considered the case of international patent exhaustion. Boesch v. Graff, 133 U.S. 697 (1890), is incorrectly cited as denying international patent exhaustion. 17

Supreme Court: Exhaustion Boesch v. Graff has nothing to do with the patentee’s first sale of a product in a foreign country: The patentee owned parallel patents for his stove component in both the United States and Germany. The patentee’s competitor sold the same stove component in Germany without a license because the competitor was making the stove component independent of the patent right (due to a “prior user right”). 18

Supreme Court: Exhaustion In Boesch v. Graff the sale of the stove component purchased from the patentee’s competitor was found to be an infringement of the United States patent. But, this was not “international patent exhaustion” because the patentee never sold the patented stove component that was imported into the United States and sold. 19

Supreme Court: Exhaustion Jazz Photo Corp. v. Int'l Trade Comm'n, 264 F.3d 1094 (Fed.Cir.2001)(Newman, J.), is the first and therefore precedential Federal Circuit case on “international patent exhaustion”. Without any reasoning, the Court simply that “[t]o invoke the protection of the first sale doctrine [of exhaustion], the authorized first sale must have occurred under the United States patent.” Jazz Photo, 264 F.3d at

Supreme Court: Exhaustion The only support given by the Federal Circuit is a citation to Boesch v. Graff, 133 U.S. at ,with a parenthetical statement of what it viewed as the holding: “[A] lawful foreign purchase does not obviate the need for license from the United States patentee before importation into and sale in the United States.” 21

Supreme Court: Exhaustion But, of course, Boesch v. Graff had nothing to do with “international patent exhaustion. FujiFilm Corp. v. Benum, __ F.3d __ (Fed. Cir. 2010)(per curiam)(Michel, C.J., Mayer, Linn, JJ.), is the most recent Federal Circuit case following the Jazz Photo denial of international patent exhaustion because that case is binding precedent (unless overturned en banc). 22

Supreme Court: Exhaustion The Supreme Court has never considered international patent exhaustion but has considered other IPR international exhaustion. The October 2010 Term of the Court will consider international copyright exhaustion in Costco Wholesale Corp. v. Omega, S.A., Supreme Court No , opinion below, Omega S.A. v. Costco Wholesale Corp., 541 F.3d 982 (9th Cir. 2008)(Smith, Jr., J.), 23

Supreme Court: Exhaustion The Supreme Court in Costco may well provide clues as to its views on international exhaustion generally, i.e., including patents, when it decides the Costco case. 24

Supreme Court: Exhaustion In Transcore, the Federal Circuit broadly interpreted the scope of exhaustion: “[T]he Supreme Court [in Quanta] reiterated unequivocally that ‘[t]he longstanding doctrine of patent exhaustion provides that the initial authorized sale of a patented item terminates all patent rights to that item[.]’” TransCore, LP v. Electronic Transaction Consultants Corp., 563 F.3d 1271, 1274 (2009)(Gajarsa, J.) (quoting QuantaComputer, Inc. v. LG Electronics, Inc., 128 S.Ct. 2109, 2115, 2121 (2008))(emphasis added). 25

Supreme Court: Exhaustion A second appeal in the same Quanta case is expected which will deal with international patent exhaustion. “Quanta II” is the second part of the Quanta case. The District Court in Quanta II said that “yes”, there is international patent exhaustion. LG Electronics, Inc. v. Hitachi, Ltd., 2009 WL (N.D.Cal. 2009)(Wilken, J.) 26

Supreme Court: Exhaustion The Federal Circuit – and then possibly the Supreme Court as well – will consider international patent exhaustion in a “Quanta II” appeal. 27

Supreme Court Decisions Thank you very much for your attention! If you have any questions you may feel free to contact me at Thank you, again!

HAROLD C. WEGNER HAROLD C. WEGNER retains his affiliation with the George Washington University Law School where he had been Director of the Intellectual Property Law Program and Professor of Law. His involvement with other academic institutions has included service as a Visiting Professor at Tokyo University. Hecontinues his patent practice as a partner at Foley & Lardner LLP. Prof. Wegner’s patent career commenced with service at the U.S. Department of Commerce as a Patent Examiner. He spent three years at the Max-Planck- InstitutfürGeistigesEigentum in Munich where he was a WissenschaftlicheMitarbeiter. He then became a Kenshuinat the Kyoto University Law Faculty under Dr. Kitagawa. Prof. Wegner is a graduate of Northwestern University (B.A.) and the Georgetown University Law Center (J.D.), where he launched his teaching career as an Adjunct Professor of Law teaching International Licensing. contact: